Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR‐mutated non–small cell lung cancer

BACKGROUND: Non‐small cell lung cancer (NSCLC) positive for activating mutations of the epidermal growth factor receptor (EGFR) gene is initially sensitive to EGFR‐tyrosine kinase inhibitors (TKIs) but eventually develops resistance to these drugs. Upregulation of the receptor tyrosine kinase AXL in...

Descripción completa

Detalles Bibliográficos
Autores principales: Nonagase, Yoshikane, Takeda, Masayuki, Azuma, Koichi, Hayashi, Hidetoshi, Haratani, Koji, Tanaka, Kaoru, Yonesaka, Kimio, Ishii, Hidenobu, Hoshino, Tomoaki, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775020/
https://www.ncbi.nlm.nih.gov/pubmed/31419057
http://dx.doi.org/10.1111/1759-7714.13166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775020/
https://www.ncbi.nlm.nih.gov/pubmed/31419057
http://dx.doi.org/10.1111/1759-7714.13166

Ejemplares similares